Protozoan and metazoan parasites are the causative agents of many neglected diseases of global health import. Because these are diseases of poor people in resource-poor areas, there has been little economic incentive to develop new drugs in the pharmaceutical industry. Attention has therefore focused on suitable molecular targets in these parasites that could be exploited for new drugs at a relatively low cost. Cysteine proteases are particularly attractive for several reasons. They are ubiquitous in parasites; they are known to be druggable; and much is known about their structure, mechanism of action, and how to inhibit them. This compendium of reviews will focus attention on selected proteases and their function.
Editor: Paul J. Brindley, George Washington University School of Medicine and Health Sciences, UNITED STATES the proteasome. As more information accrues, those proteases will also be reviewed. Likewise, the regulation of cysteine proteases in parasites is an important research focus, including work on protein inhibitors like chagasin [6] .
Cysteine proteases are not unique to parasites [7, 8] . Homologues can be found in vertebrates including animal and human hosts. However, there is an important and frequently overlooked difference. Human homologues, such as the cathepsins, are often found in high concentration in intracellular organelles like the lysosome. It has been estimated that in some cases, the concentration may be in the millimolar range [9] . In addition, there is redundancy in human cysteine proteases not found in the simpler parasite genomes. This is likely one reason why gene knockouts of cathepsins in mice are not lethal and, in fact, often have minimal consequences [10] . Therefore, in evaluating protease inhibitors as potential drugs, one must consider "biological selectivity" in addition to biochemical selectivity. In other words, a specific protease inhibitor may show no selectivity for parasite versus host protease targets but may still become an effective drug because of the location of the parasite target. Parasites are often in a more vulnerable location (like the bloodstream or intestinal lumen for helminth parasites). Or their proteases may be on their cell surface (as with Trypanosoma cruzi amastigotes). Furthermore, successful parasites must be able to scavenge small molecules from the host, so one might also hypothesize that protease inhibitors could be selectively taken up and concentrated in a parasite versus adjacent host tissue. P1' to P3' represent amino acid sidechains from cleavage site to C terminus. The nomenclature was first defined by Schecter and Berger [3] .
